What's more, in order to really make the point that anti-CD180 Ab treatment relieves the lupus-symptoms of IMQ-treated mice and MRL/lpr mice through regulating the activations of macrophages and DCs, it needs to use a cell type specific knockout system, such as the MRL/lpr mice lacking myeloid cells. Here, CD180 is linked to systemic lupus erythematosus.